Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection

W. Barcellini, G. P. Rizzardi, G. Poli, G. Tambussi, C. Velati, P. L. Meroni, A. G. Dalgleish, A. Lazzarin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We studied determinants of chronic inflammation and/or immune activation in plasma from patients in the transition from primary to early chronic HIV- 1 infection. The following parameters were estimated in seven patients over time: plasma concentrations of soluble CD8 (sCD8), tumor necrosis factor α (TNF-α), soluble TNF receptor type II (sTNFRII), interleukin 6 (IL-6), soluble IL-6 receptor (sIL6R), IL-10, transforming growth factor β1 (TGF- β1), along with CD4- and CD8-positive T cell counts, p24 antigenemia, and clinical evaluation. Results showed that concentrations of sCD8, TNF-α, and sTNFRII, and peripheral CD8-positive lymphocyte counts, were significantly increased in patients, compared to HIV-negative controls, and showed a trend toward normal values over time. Levels of IL6, sIL6R, IL-10, and TGF-β1 did not differ from those of controls and did not change over time. Heterogeneity was observed among the patients in terms of CD4-positive T cell depletion, levels of sCD8, concentrations of TNF-α/sTNFRII, and clinical outcome. These data indicate that in the transition phase from primary acute to chronic and asymptomatic infection the host immune activation in response to the virus is highly heterogeneous and that the sustained rise in TNF-α and its receptor may represent an important therapeutic target in early disease. The persistence of a state of chronic inflammation and/or immune activation could influence the progression of disease independently from CD4-positive T cell counts.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume12
Issue number4
Publication statusPublished - 1996

Fingerprint

Cytokine Receptors
Tumor Necrosis Factor Receptors
HIV Infections
HIV-1
Interleukin-6 Receptors
Tumor Necrosis Factor-alpha
T-Lymphocytes
Interleukin-10
Interleukin-6
Cell Count
CD8-Positive T-Lymphocytes
Inflammation
Patient Transfer
Asymptomatic Infections
Phase Transition
Lymphocyte Count
Transforming Growth Factors
Disease Progression
Reference Values
HIV

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. / Barcellini, W.; Rizzardi, G. P.; Poli, G.; Tambussi, G.; Velati, C.; Meroni, P. L.; Dalgleish, A. G.; Lazzarin, A.

In: AIDS Research and Human Retroviruses, Vol. 12, No. 4, 1996, p. 325-331.

Research output: Contribution to journalArticle

@article{931d7815f4c24442bd1f3f5d172a3340,
title = "Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection",
abstract = "We studied determinants of chronic inflammation and/or immune activation in plasma from patients in the transition from primary to early chronic HIV- 1 infection. The following parameters were estimated in seven patients over time: plasma concentrations of soluble CD8 (sCD8), tumor necrosis factor α (TNF-α), soluble TNF receptor type II (sTNFRII), interleukin 6 (IL-6), soluble IL-6 receptor (sIL6R), IL-10, transforming growth factor β1 (TGF- β1), along with CD4- and CD8-positive T cell counts, p24 antigenemia, and clinical evaluation. Results showed that concentrations of sCD8, TNF-α, and sTNFRII, and peripheral CD8-positive lymphocyte counts, were significantly increased in patients, compared to HIV-negative controls, and showed a trend toward normal values over time. Levels of IL6, sIL6R, IL-10, and TGF-β1 did not differ from those of controls and did not change over time. Heterogeneity was observed among the patients in terms of CD4-positive T cell depletion, levels of sCD8, concentrations of TNF-α/sTNFRII, and clinical outcome. These data indicate that in the transition phase from primary acute to chronic and asymptomatic infection the host immune activation in response to the virus is highly heterogeneous and that the sustained rise in TNF-α and its receptor may represent an important therapeutic target in early disease. The persistence of a state of chronic inflammation and/or immune activation could influence the progression of disease independently from CD4-positive T cell counts.",
author = "W. Barcellini and Rizzardi, {G. P.} and G. Poli and G. Tambussi and C. Velati and Meroni, {P. L.} and Dalgleish, {A. G.} and A. Lazzarin",
year = "1996",
language = "English",
volume = "12",
pages = "325--331",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection

AU - Barcellini, W.

AU - Rizzardi, G. P.

AU - Poli, G.

AU - Tambussi, G.

AU - Velati, C.

AU - Meroni, P. L.

AU - Dalgleish, A. G.

AU - Lazzarin, A.

PY - 1996

Y1 - 1996

N2 - We studied determinants of chronic inflammation and/or immune activation in plasma from patients in the transition from primary to early chronic HIV- 1 infection. The following parameters were estimated in seven patients over time: plasma concentrations of soluble CD8 (sCD8), tumor necrosis factor α (TNF-α), soluble TNF receptor type II (sTNFRII), interleukin 6 (IL-6), soluble IL-6 receptor (sIL6R), IL-10, transforming growth factor β1 (TGF- β1), along with CD4- and CD8-positive T cell counts, p24 antigenemia, and clinical evaluation. Results showed that concentrations of sCD8, TNF-α, and sTNFRII, and peripheral CD8-positive lymphocyte counts, were significantly increased in patients, compared to HIV-negative controls, and showed a trend toward normal values over time. Levels of IL6, sIL6R, IL-10, and TGF-β1 did not differ from those of controls and did not change over time. Heterogeneity was observed among the patients in terms of CD4-positive T cell depletion, levels of sCD8, concentrations of TNF-α/sTNFRII, and clinical outcome. These data indicate that in the transition phase from primary acute to chronic and asymptomatic infection the host immune activation in response to the virus is highly heterogeneous and that the sustained rise in TNF-α and its receptor may represent an important therapeutic target in early disease. The persistence of a state of chronic inflammation and/or immune activation could influence the progression of disease independently from CD4-positive T cell counts.

AB - We studied determinants of chronic inflammation and/or immune activation in plasma from patients in the transition from primary to early chronic HIV- 1 infection. The following parameters were estimated in seven patients over time: plasma concentrations of soluble CD8 (sCD8), tumor necrosis factor α (TNF-α), soluble TNF receptor type II (sTNFRII), interleukin 6 (IL-6), soluble IL-6 receptor (sIL6R), IL-10, transforming growth factor β1 (TGF- β1), along with CD4- and CD8-positive T cell counts, p24 antigenemia, and clinical evaluation. Results showed that concentrations of sCD8, TNF-α, and sTNFRII, and peripheral CD8-positive lymphocyte counts, were significantly increased in patients, compared to HIV-negative controls, and showed a trend toward normal values over time. Levels of IL6, sIL6R, IL-10, and TGF-β1 did not differ from those of controls and did not change over time. Heterogeneity was observed among the patients in terms of CD4-positive T cell depletion, levels of sCD8, concentrations of TNF-α/sTNFRII, and clinical outcome. These data indicate that in the transition phase from primary acute to chronic and asymptomatic infection the host immune activation in response to the virus is highly heterogeneous and that the sustained rise in TNF-α and its receptor may represent an important therapeutic target in early disease. The persistence of a state of chronic inflammation and/or immune activation could influence the progression of disease independently from CD4-positive T cell counts.

UR - http://www.scopus.com/inward/record.url?scp=0029966349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029966349&partnerID=8YFLogxK

M3 - Article

C2 - 8906993

AN - SCOPUS:0029966349

VL - 12

SP - 325

EP - 331

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -